Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-35
SponsorAhmed Alshimy

About this trial

Fibromyalgia is the third most common musculoskeletal condition in terms of prevalence, after lumbar pain and osteoarthritis. Its prevalence is around 2-4 % and is more frequent in women than in men; the prevalence is highest in age the range of 40-60 years.

Eligibility criteria

Qualifiers

Patients fibromyalgia from both genders.

The duration of fibromyalgia is more than 6 month (all patients with history of cervical or lumbar pain) and following diagnosis of FM using the 2016 revised FM criteria, on the basis of the ACR-2010 criteria.

Their ages will be ranged from 25-35 years old.

They will be medically stable and have sufficient cognitive abilities that enable them to understand and follow instruction according to Montreal Cognitive Assessment (MoCA) >26.

Disqualifiers

Other Neurological diseases as stroke , multiple sclerosis, Parkinson's disease and motor neuron disease

Pacemaker

Spinal fusion-cervical or lumbar

Metal implants in the spine

Trial design

Treatments tested in this trial

  • Aerobic Exercises
  • Transcutaneous electrical nerve stimulation

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ahmed Alshimy

Lead sponsor

AlRyada University for Science & Technology

Sponsor institution